Josep Tabernero, MD, PhD
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has backed approval of TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of adult patients with metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction (GEJ), following treatment with at least 2 prior systemic regimens for advanced disease.
TAS-102 was previously approved in the EU for the treatment of patients with colorectal cancer (CRC). In the United States, TAS-102 has approved indications for CRC and gastric/GEJ cancer.
Arkenau H-T, Tabernero J, Shitara K, et al. TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Presented at: 2018 ESMO Congress; October 19-23, 2018; Munich, Germany. LBA25.
... to read the full story